14.63 -0.05 (-0.34%)
Pre-Market: 8:28AM EDT
|Bid||14.62 x 800|
|Ask||14.71 x 2200|
|Day's Range||14.66 - 15.35|
|52 Week Range||13.45 - 36.65|
|Beta (3Y Monthly)||2.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.54|
Coatue Management is a New York City-based hedge fund that was launched back in 1999 by Philippe Laffont. The fund provides additional office in Menlo Park, California. At the end of 2016, it held around $10.25 billion in assets under management. Coatue Management looks for the stocks to invest in from the technology sector, utilizing […]
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
-- Mallinckrodt's CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1 -- STAINES-UPON-THAMES, United Kingdom , May 14, 2019 /PRNewswire/ -- Mallinckrodt ...
NEW YORK , May 13, 2019 /PRNewswire/ -- Glencore plc (GLNCY) Lifshitz & Miller announces investigation into possible securities laws violations regarding allegations that GLNCY and other trading firms ...
The company has recently been embroiled in two whistleblower lawsuits that have negatively impacted the company's stock. Shares of Mallinckrodt Pharmaceuticals MNK seesawed Tuesday morning, swinging up by as much as 16.4% before the markets opened but trading lower after the company reported otherwise strong first-quarter earnings and raised its profit outlook for the year. Mallinckrodt attributed its strong quarterly performance to sales of hospital products and generic drugs.
Mallinckrodt Plc NYSE:MNKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is extremely high for MNK with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MNK totaled $2.63 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Mallinckrodt (MNK) delivered earnings and revenue surprises of 12.14% and 2.47%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Mallinckrodt PLC shot up 13% in premarket trade Tuesday, after the drug maker reported first-quarter earnings and sales that beat expectations, and raised its full-year outlook. The company swung to net income of $154.9 million, or $1.83 a share, from a loss of $18.0 million, or 21 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS rose 20% to $1.94, above the FactSet consensus of $1.70. Net sales rose 4.7% to $790.6 million, above the FactSet consensus of $766.3 million. Specialty brands sales fell 0.2% to $547.3 million but topped the FactSet consensus of $539.8 million, and specialty generics sales grew 18% to $243.3 million to beat expectations of $228.3 million. For 2019, the company raised its adjusted EPS guidance range to $8.30 to $8.60 from $8.10 to $8.40. The stock, which closed at a one-year low on May 1, has tumbled 21% over the past three months through Monday, while the SPDR Health Care Select Sector ETF has edged up 1.0% and the S&P 500 has gained 8.4%.
The Surrey, Britain-based company said it had net income of $1.83 per share. Earnings, adjusted for one-time gains and costs, were $1.94 per share. The results beat Wall Street expectations. The average ...
-- Full data to be presented in detail by CPP at Digestive Disease Week (DDW) conference on May 19, 2019 at 5:19 pm Pacific Time -- TUCSON, Ariz. and STAINES-UPON-THAMES, United Kingdom , May 7, 2019 /PRNewswire/ ...
- Net sales up 4.7%, or 5.0% on a constant-currency basis, on $790.6 million , led by strong performance of hospital products and the Specialty Generics and Amitiza segment - Diluted income per share from ...
STAINES-UPON-THAMES, United Kingdom, May 6, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced preliminary results of a planned interim analysis from the company's Phase 4 registry assessing the use of INOmax® (nitric oxide) gas, for inhalation, for premature (27 to less than 34 weeks gestational age) neonates versus term and near-term neonates (34 weeks and greater gestational age) with pulmonary hypertension (PH). The primary outcome measure compares the incidence of mechanically ventilated subjects with PH who achieve at least a 25 percent improvement in Oxygenation Index (OI) from baseline, or Surrogate Oxygenation Index (SOI) for subjects who are not ventilated, between gestation age groups.
SAN DIEGO , May 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP has commenced an investigation into whether certain officers and directors of Mallinckrodt PLC (NYSE: MNK) violated ...
STAINES-UPON-THAMES, United Kingdom, May 2, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, has completed the controlled, double-blind, randomized second phase of the ongoing Phase 4, multicenter study assessing the efficacy and safety of Acthar® Gel in patients with persistently active rheumatoid arthritis (RA) who were previously treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. Acthar Gel is U.S. Food and Drug Administration (FDA)-approved as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in RA including juvenile RA (selected cases may require low-dose maintenance therapy).
As the opioid crisis continues to rage in the United States, publicly traded companies that manufacture, market, or sell the prescription drugs at the center of the epidemic are facing shareholder resolutions for governance reforms and improved disclosure of risks around their involvement in the making or sale of the drugs. In the process, this effort is turning the spotlight to how major fund companies and other big investors are casting their proxy votes in 2019. Starting this week and continuing over the next month, shareholders of Johnson & Johnson JNJ , Mallinckrodt MNK , and CVS Health CVS will be voting on opioid-related resolutions.
NEW YORK, May 01, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Mallinckrodt plc (NYSE: MNK). Our investigation concerns whether.
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.
BOSTON, May 01, 2019 -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating whether Mallinckrodt PLC (“Mallinckrodt” or the.
News of the department's decision to intervene in the lawsuits after conducting an investigation into the whistleblowers' allegations sent the stock price of Mallinckrodt Plc down nearly 14 percent on Tuesday. The lawsuits, filed in federal court in Philadelphia, claimed Questcor Pharmaceuticals, which Mallinckrodt acquired in 2014, defrauded government healthcare programs by illegally marketing H.P. Acthar Gel. The drug is used to treat infantile spasms and multiple sclerosis.